A comparison of enoxaparin with unfractionated heparins in patients with coronary heart disease in an emergency department in rural South Indian tertiary care teaching hospital

Indian Journal of Pharmacology

Volumn 47, Issue 1, 2015, Pages 90-94

  Ahmad, Akram ^a,b   Patel, Isha ^c   Asani, Himani ^b   Jagadeesan, M ^b   Parimalakrishnan, S ^b   Selvamuthukumaran, S ^b  

^a UCSI UNIVERSITY   (Malaysia)

^b ANNAMALAI UNIVERSITY   (India)

^c SHENANDOAH UNIVERSITY   (United States)

Author keywords

Anticoagulant; Coronary heart disease; Efficacy; Enoxaparin; Safety; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; FIBRINOLYTIC AGENT;

ADULT; AGED; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING TENDENCY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; COST OF ILLNESS; COUGHING; DRUG COST; DRUG INDUCED HEADACHE; ELECTROCARDIOGRAM; EMERGENCY WARD; FEMALE; HUMAN; HYPOKALEMIA; INDIAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROTHROMBIN TIME; RECURRENT DISEASE; TEACHING HOSPITAL; TERTIARY HEALTH CARE; COMBINATION DRUG THERAPY; CORONARY DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; ELECTROCARDIOGRAPHY; EMERGENCY HEALTH SERVICE; HOSPITAL COST; INDIA; MIDDLE AGED; PROSPECTIVE STUDY; RURAL HEALTH CARE; TERTIARY CARE CENTER; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ASPIRIN; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; EMERGENCY SERVICE, HOSPITAL; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HOSPITAL COSTS; HOSPITALS, TEACHING; HUMANS; INDIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTHROMBIN TIME; RURAL HEALTH SERVICES; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922986194     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.150360     Document Type: Article

References (20)

1. Engelgau MM, Karan A, Mahal A. The Economic impact of non-communicable diseases on households in India. Global Health 2012;8:9.
2. Ghaffar A, Reddy KS, Singhi M. Burden of non-communicable diseases in South Asia. BMJ 2004;328:807-10.
3. th ed. Churchill Livingstone Elsevier Ltd. 2008. p. 280, 336-7.
4. Huffman MD. Center for Chronic Disease Control, Coronary Heart Disease in India. Available from: http://www.sancd.org/uploads/pdf/factsheet_CHD.pdf. [Last accessed on 2013 Mar 30].
5. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008;94:16-26.
6. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005;112:3547-53.
7. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
8. rd ed. New Delhi: Delhi Society for Promotion of Rational Use of Drugs, B I Publishing House Pvt. Ltd.; 2009. p. 116-24.
9. Misra UK, Kalita J, Chandra S, Kumar B, Bansal V. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: A randomized controlled trial. Eur J Neurol 2012;19:1030-6.
10. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126:3097-137.
11. Amane HS, Burte NP. A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris. Indian J Pharmacol 2011;43:703-6.
12. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA Jr, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001;83-A: 336-45.
13. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
14. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334:682-7.
15. Korovesis S, Karvouni E, Karabinos I, Giazitzoglou E, Papadopoulos A, Katritsis D. Comparison of enoxaparin and unfractionated heparin in coronary angioplasty. Hellenic J Cardiol 2005;46:46-51.
16. Keeling D, Davidson S, Watson H, Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. The management of heparin-induced thrombocytopenia. Br J Haematol 2006;133:259-69.
17. Antman EM. The search for replacements for unfractionated heparin. Circulation 2001;103:2310-4.
18. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998;98:294-9.
19. Montalescot G, Collet JP, Choussat R, Ankri A, Thomas D. A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients. Int J Cardiol 2000;72:293-4.
20. Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000;36:110-4.